Origin Materials, Inc. (ORGN)
NASDAQ: ORGN · Real-Time Price · USD
0.8485
-0.0318 (-3.61%)
At close: Aug 6, 2025, 4:00 PM
0.8255
-0.0230 (-2.71%)
After-hours: Aug 6, 2025, 7:59 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 3.00, which predicts a 253.57% increase from the current stock price of 0.85.
Price Target: $3.00 (+253.57%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 16, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $1.35 → $3 | Hold → Strong Buy | Upgrades | $1.35 → $3 | +253.57% | Aug 16, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades $2 | Strong Buy → Hold | Downgrades | $2 | +135.71% | Aug 11, 2023 |
| Credit Suisse | Credit Suisse | Buy Maintains $7 → $6 | Buy | Maintains | $7 → $6 | +607.13% | Aug 10, 2023 |
| Credit Suisse | Credit Suisse | Buy Initiates $7 | Buy | Initiates | $7 | +724.99% | Oct 14, 2022 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $10 → $7 | Hold | Maintains | $10 → $7 | +724.99% | Mar 1, 2022 |
Financial Forecast
Revenue This Year
46.67M
from 31.28M
Increased by 49.18%
Revenue Next Year
114.24M
from 46.67M
Increased by 144.81%
EPS This Year
-0.43
from -0.58
EPS Next Year
-0.32
from -0.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 48.0M | 117.6M |
| Avg | 46.7M | 114.2M |
| Low | 44.8M | 109.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 53.6% | 152.0% |
| Avg | 49.2% | 144.8% |
| Low | 43.3% | 135.2% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.44 | -0.33 |
| Avg | -0.43 | -0.32 |
| Low | -0.41 | -0.30 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.